Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 12:7:88.
doi: 10.1186/1750-1172-7-88.

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study

Affiliations

Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study

Nadine A M E van der Beek et al. Orphanet J Rare Dis. .

Abstract

Background: Due partly to physicians' unawareness, many adults with Pompe disease are diagnosed with great delay. Besides, it is not well known which factors influence the rate of disease progression, and thus disease outcome. We delineated the specific clinical features of Pompe disease in adults, and mapped out the distribution and severity of muscle weakness, and the sequence of involvement of the individual muscle groups. Furthermore, we defined the natural disease course and identified prognostic factors for disease progression.

Methods: We conducted a single-center, prospective, observational study. Muscle strength (manual muscle testing, and hand-held dynamometry), muscle function (quick motor function test), and pulmonary function (forced vital capacity in sitting and supine positions) were assessed every 3-6 months and analyzed using repeated-measures ANOVA.

Results: Between October 2004 and August 2009, 94 patients aged between 25 and 75 years were included in the study. Although skeletal muscle weakness was typically distributed in a limb-girdle pattern, many patients had unfamiliar features such as ptosis (23%), bulbar weakness (28%), and scapular winging (33%). During follow-up (average 1.6 years, range 0.5-4.2 years), skeletal muscle strength deteriorated significantly (mean declines of -1.3% point/year for manual muscle testing and of -2.6% points/year for hand-held dynamometry; both p<0.001). Longer disease duration (>15 years) and pulmonary involvement (forced vital capacity in sitting position <80%) at study entry predicted faster decline. On average, forced vital capacity in supine position deteriorated by 1.3% points per year (p=0.02). Decline in pulmonary function was consistent across subgroups. Ten percent of patients declined unexpectedly fast.

Conclusions: Recognizing patterns of common and less familiar characteristics in adults with Pompe disease facilitates timely diagnosis. Longer disease duration and reduced pulmonary function stand out as predictors of rapid disease progression, and aid in deciding whether to initiate enzyme replacement therapy, or when.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical features in Pompe disease. Atrophy of the quadriceps muscle (A), scapular winging (B), and ptosis (C) as notable clinical features in adults with Pompe disease. Photographs are printed with permission of the patients.
Figure 2
Figure 2
Muscle weakness in adults with Pompe disease. Distribution of skeletal muscle weakness (A), severity of muscle weakness of the individual muscle groups (B), and involvement of the individual muscles over time (C) in 94 adults with Pompe disease.
Figure 3
Figure 3
Longitudinal changes in muscle strength. Rate of disease progression measured by manual muscle testing (MRC sumscore) (A) and hand-held dynamometry (HHD sumscore) (B) related to follow-up duration measured from time of inclusion in the study for 66 adults with Pompe disease. The figure shows the measured values and regression lines at group level for the following subgroups: 1) Patients with normal pulmonary function (FVC ≥80% predicted) and disease duration <15 years (circles, black line); 2) patients with normal pulmonary function (FVC ≥80% predicted) and disease duration ≥ 15 years (red squares, red line); 3) patients with abnormal pulmonary function (FVC <80% predicted) and disease duration <15 years (green triangles, green line); and 4) patients with abnormal pulmonary function (FVC <80% predicted) and disease duration ≥ 15 years (blue asterisks, blue line).
Figure 4
Figure 4
Muscle strength in individual muscle groups measured by hand-held dynamometry. Values for individual patients are shown at baseline (black squares) and during follow-up (last measured value) (open squares). Mean and standard error of the mean are given for each muscle group.
Figure 5
Figure 5
Longitudinal changes in pulmonary function. Decline in pulmonary function in the upright seated (A) and supine (B) positions related to follow-up duration. Circles represent the measured values, the line represents the mean regression line at a group level.

References

    1. Pompe JC. Over idiopathische hypertrofie van het hart. Ned Tijdschr Geneeskd. 1932;76:304–311.
    1. Engel AG, Gomez MR, Seybold ME, Lambert EH. The spectrum and diagnosis of acid maltase deficiency. Neurology. 1973;23:95–106. doi: 10.1212/WNL.23.1.95. - DOI - PubMed
    1. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;372:1342–1353. doi: 10.1016/S0140-6736(08)61555-X. - DOI - PubMed
    1. Engel AG. Franzini-Armstrong: Myology. New York: McGraw-Hill; 2004.
    1. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA 3rd, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen sto rage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3:132–138. - PubMed

Publication types